Virtual Crossmatch in Kidney Transplantation
|
|
- Benjamin Small
- 5 years ago
- Views:
Transcription
1 Virtual Crossmatch in Kidney Transplantation Shiva Samavat Associate Professor of Nephrology Labbafinejad Hospital SBMU
2 All transplant candidates are screened to determine the degree of humoral sensitization to HLA antigens. Sensitization to HLA is of great concern in certain candidate populations: multiple blood transfusions, a previous kidney transplant, or from pregnancy. 2
3 3
4 Y bea d Pooled panel bead Application Y bea d Y HLA Antibody HLA Detection Antibody bea d Phenoty pe bead Single antigen bead Screening Specification Specification Relative Antigen density Low Intermediate High Antigen composition per bead HLA I/II HLA I or II phenotype of one person Single allele antigen 4
5 Single Antigen Beads Could Help in: Calculated panel-reactive antibody (cpra), which is presently the best estimate of likelihood of a positive XM/DSA to a randomly selected donor. Virtual crossmatching (VXM) to identify DSA pretransplant, in turn facilitating allocation and risk assessment. Detection of antibody against rare HLAs. 5
6
7 Approach to sensitized patients Patients without living donor Patients with a living donor Allocation System No DSA & Negative Cross-match DSA & Positive Cross-match Transplant Paired Kidney Exchange Desensitization Protocols cpra; KDPI; EPTS Unacceptable antigen Desensitization while on waiting list Virtual Crossmatch
8 Virtual crossmatch The results of SPI testing can be used to predict the results of cell-based compatibility assays and are often referred to as a virtual crossmatch. Virtual crossmatch predicts actual crossmatch results.
9 The rationale for moving to virtual crossmatching: Use methods that mimic the sensitivity of the final crossmatch. Reduce the time and cost for deceased donor workup. Deceased donor allocation for highly sensitized patients.
10 It requires active communication between: The HLA laboratory staff Transplant coordinators Transplant physicians
11
12 Defining the HLA unacceptable antigens. Methods for deceased donor HLA typing (the level of resolution). Criteria to assess HLA compatibility.
13 Unacceptable antigen mismatches The determination of UAM is a critical decision step because: With increasing number of forbidden antigen, the patient s chance to receive an organ offer diminishes dramatically. Conversely, unrecognized UAM frequently leads to inferior graft survival and futile organ shipments due to a positive crossmatch in the recipient center.
14 Most appropriate test and sensitivity level for the determination of UAM
15
16
17
18 Human Immunology. 2017; 78 (1): 19-23
19
20 Depending on the algorithm, these patients had a vpra between 60% and 71.5%, translating into a potential prolongation of waiting time between 1.5 and 1.8 years, respectively. An increase in vpras of 1% could be outweighed by an additional waiting time of 2.5 weeks.
21 The decision which algorithm to use will remain a judgement call for HLA laboratories and transplant physicians and has to be balanced between an unknown prolongation of waiting time for a considerable number of potentially low risk patients and maximization of success rates for those patients transplanted.
22 Defining the HLA unacceptable antigens. Methods for deceased donor HLA typing (the level of resolution). Criteria to assess HLA compatibility.
23 HLA Typing of Donor Needs a rapid and accurate technique: SSP; SSOP; RT-PCR 2-digit vs 4-digit typing (DQB1*03 vs DQB1*03:01) Locus to be typed: HLA-DQA, DPA, C are not routinely typed. In a highly sensitized recipient: High resolution typing HLA-DQA, DPA, C
24 Assessment of HLA compatibility SABs are used to define broad and allele specific antibodies. Donor- recipient matching could be done at various levels: Allele matching Epitope matching CREG matching
25 Allele matching could be done by: High-resolution (four-digit) typing. Online allele frequency databases Given the likelihood of increased allele-specific antibodies in highly sensitized patients, it may be time to re-examine the need for mandated high resolution deceased donor typing.
26
27
28
29
30
31
32
33 Out of a total of 6924 procured kidneys from the 22 OPOs, 520 (7.5%) were exported out of the DSA for hpra recipients. Of these 520 kidneys, 402 (77.3%) were transplanted into the intended recipient (IR), 100 (19.2%) were transplanted into URs, and 18 (3.5%) were discarded.
34 Negative XM results were confirmed prior to kidney export. Pre-export virtual XM results only 96.2% of kidneys with pre-export tissue XM went into IRs, compared to 80.7% for those who had virtual XM only, and 54.2% who had no XM done prior to shipping
35 Kidneys were more likely to be transplanted into the intended recipient when tissue XMs were done prior to export of the kidney. A seemingly compatible transplant may in fact be incompatible due to unidentified allele-specific antibodies.
36 Many of these XM issues may be related to transplant centers not listing antigens at the DP and/or DQA locus. Both V-XM and FC-XM detect alloantibodies based on fixing to a solid phase (donor cells or beads), while CDC-XM and cfc-xm cover only alloantibodies that bind complement and result in cell lysis.
37 Avoidance of donors with HLA antigens against whom C1q-binding antibodies were detected would have prevented all positive crossmatches due to HLA antibodies. Transplant immunology, Vol 4, March 2017, Pages 17-21
38 Screening for complement-binding antibodies by SPI in patients on the waiting list may further improve the identification of those donor-recipient-combinations, in whom the CDC-crossmatch would become positive. In patients with relatively low C1q-PRA, all C1qpositive antibodies could be assigned as UAG to safely avoid positive CDC-crossmatches.
39 DSA MFI had poor correlation with both T cell (R2 = 0.493) and B cell (R2 = 0.571) FCXM MCS.
40 VXM Limitations Issues of incomplete donor HLA genotype Technical factors specific to SPI: Use of appropriate MFI cutoff values False positive reactions against the microbeads Non-native HLA epitopes False negative SPI results due to inhibition by interfering substances or prozone effects
41 Technical aspects of SPI underlie majority of VCXM failures Anti-HLA antibodies not listed Anti-HLA antibodies with allelic specificity Anti-HLADP antibodies, False negative SPI results (including antibodies against non-hla antigens).
42 Prozone effect false negative SPI results limit VCXM 6.6 ± 6.7 new anti-hla antibodies/sample at 1:10 serum dilution
43 Cumulative effects of multiple low-mfi DSA Multiple low-titer DSAs can have additive or synergistic effects and result in positive CXM. Ability of VCXM using sum MFI of all DSA to predict positive FCXM when VCXM based on single maximum DSA MFI did not predict positive FCXM.
44 Standard SPI does not detect all alloantibodies present capable of causing positive FCXM
45 IgM Anti-HLA Antibodies Anti HLA class I Reactive Antigens IgG High Risk Antigens (MFI >1000) None Moderate Risk Antigens (MFI ) None Anti HLA class II Reactive Antigens IgG High Risk Antigens (MFI >1000) Moderate Risk Antigens (MFI ) None None Anti HLA class I Reactive Antigens IgM High Risk Antigens (MFI >1000) A*23:01A*34:01B*13:01B*27:05B*45:01B*57:01 A*24:02A*68:01B*14:02B*38:01B*49:01- A*25:01- A*26:01B*07:02- B*08:01B*15:01- B*18:01B:40:01- B*44:02B*51:01- B*52:01- A*02:01- A*11:01- A*32:01 Moderate Risk Antigens (MFI ) Reactive Antigens High Risk Antigens (MFI >1000) Moderate Risk Antigens (MFI ) DRB1*01:03- DRB1*04:05 DRB1*10:01- DRB1*16:01- DRB1*04:04DQB1*04:02- DQB1*03:01- DQB1*03:02
46 Reasons for a False-positive Virtual Crossmatch HLA molecules might be denatured during the production process exposing novel epitopes. The detected HLADSAs might be directed against epitopes of the HLA molecules, which are accessible on SAB but not in vivo, and thus are probably not pathogenic (i.e. epitopes in the proximity of the cell membrane)
47 Summary VCXM is an important and powerful tool for organ allocation, and is increasingly used by transplant programs as a primary means for prospective assessment of immunologic compatibility. SPI and VCXM are imperfect.
48 Increases transplantation probability in highly sensitized patients. Predicts actual crossmatch results Avoidance of unnecessary organ shipment Save time
49 Selection of cutoff values Precise HLA typing of donor Determination of C1q binding antibodies Sample dilution to overcome prozone effect Extended HLA SPI IgM antibodies
50 Virtual Crossmatch in Kidney Transplantation: Is It Better Than Actual Crossmatch?
51 Thanks for Your Attention
52 Anti-HLA antibodies were tested with Luminex single antigen. The recipients and donors were typed for HLA-A, -B, -DRB1, DQB1, the donors were also typed for -C, by SSP DNA-typing. Unacceptable antigens for the V-XM were considered : class I or class II HLA antibodies with MFI > A V-XM was performed for all deceased donors aged <65 years Before transplantation a final T and B lymphocyte CDC-XM: going ahead if the result was negative.
53 During the study period a total of 57 kidney grafts were initially allocated, although only 52 transplantations went ahead as the CDC-XM was positive in 5 patients (negative predictive value of the V-XM: 91.3%)
54 MFI >2000 are assigned as unacceptable MFI: 1000 to 2000 are assigned as watch
55 The false negative V-XMs were related with: Failures in introduction of the data. HLA antigens not initially considered to be unacceptable (HLA antibodies in a single historical serum sample or HLA antibodies with a low MFI). Possible presence of non-hla antibodies. DP antibodies were related with the development of AMR
56 Restrictive VCXM criteria ensuring immunologic compatibility could unnecessarily exclude potentially compatible transplants (particularly for highlysensitized patients). Less restrictive VCXM approaches have higher risk of unpredicted incompatibility and resulting organ redirection, discard, or rejection.
57
58
59
60
61
62
63 A CDC-crossmatch prior to transplantation should be maintained in highly immunized patients: assignment of all C1q-binding antibodies as UAG would more or less prevent allocation of organs to recipients with extremely high vpra. CDC-crossmatch in patients with a recent immunizing event or patients with strong suspicion of possibly clinically relevant Non-HLA antibodies. (serum drawn immediately before transplantation)
64 It is important to note however that a cell-based XM could be negative in the context of an actual allele-specific donor antibody. Weak DSA not resulting in positive cell-based XM may still present a risk of antibody-mediated rejection post-transplant.
65
66 Multiple low-titer DSAs can have additive or synergistic effects and result in positive CXM. 23 cases where max MFI < 3000 and sum MFI>= 3000 correlated with a positive FCXM. 21 cases of a negative FCXM in the setting of max MFI < 3000 and sum MF>= Negative FCXM with positive VCXM using sum MFI occurred about 3-times as frequently when the multiple DSA were restricted to class II HLA antigens as compared to the
67
68
69 The most common approach to deal with a potential allelespecific antibody was to request donor cells to perform a prospective cell-based crossmatch (XM). might not have been available in a timely manner A physical XM can very easily result in a false negative reaction, providing misleading information to those centers willing to transplant across DSA as long as the physical XM was negative. Another factor that can contribute to false negative crossmatches is when the physical XM is performed without pronase treatment of donor cells
70 Acceptable antigens are defined by the lack of antibody reactivity in complement-dependent cytotoxicity assays using target cells mismatched for a single HLA antigen, or single antigen-expressing cell lines.
71
72
73 It is commonly accepted to define all those HLA antibody specificities as UAM that are cytotoxic in cell-based complement-dependent cytotoxicity (CDC) assays The relevance of a positive SAB test result, however, is less clear as the positive predictive value of a DSA detected by Luminex testing for the occurrence of early AMR and graft loss in an individual patient is low. neither the prognostic value of different MFI levels nor specific MFI cut-offs for the segregation of patients at risk from those without have clearly been established so far.
74 It has been recommended to define DSA that are positive in solid phase but negative in cell-based assays only as UAM if they can be explained by a patient's immunization history HLA were defined as UAM if HLA-Abs were found in CDC assays or if the Luminex assay revealed HLA-Abs directed against HLA from previously failed grafts.
75 Because cadaver donors had been routinely typed for HLA-A, -B, DR, and -DQB molecules by sequence-specific primer methods, we did not consider antihla-c, -DQA, and -DPB DSA in performing vxm. When relevant, donors were typed for these molecules. The limited specificity with both of the XM techniques (CDC-XM, 74%; FC-XM, 79%) was due to the presence of acceptable DSA (MFI <5,000) present in some serum samples. In particular, patient sera contained acceptable DSA and/or antidqa/dpb DSA in 145 (29%) of the 507 a-xms.
76 From the frequency of UAM in the ET population, the so called virtual panel reactivity (vpra) value is calculated which reflects the percentage of organ donors that are not eligible for the patient. vpra is allocation relevant, and dependent on the height of the vpra value, patients can receive up to 100 additional points during organ allocation via the mismatch probability score in which blood group compatibility and donor and recipient HLA typings are also considered.
77 Kidney transplant candidates on the ET waiting list receive organ offers only from UAM-negative donors during the organ allocation process, a procedure which is designated as virtual XM (vxm). This measure minimizes the number of cases with a prolonged cold ischemia time by avoiding organ shipment to another center because of a positive XM result at the recipient center.
78 Methods for determination of UAM Sensitive solid-phase assays must be used in addition to the CDC technique. The CDC technique detects complement fixing antibodies in high-titer sera. Sera of all patients are tested using the SABmethod for the presence of HLA class I and class II IgG antibodies, at least at the time of active listing of the patient on the waiting list. For the determination of UAM, B-cell-specific cytotoxic techniques should also be used under the usage of dithiothreitol (DTT) (B-CDCPRA and B-CDC-PRA-DTT).
79 The following precautions should be taken in the praxis of single antigen solid-phase assays: Minimize prozone effects. The patient s own four-digit allele specificities should be excluded in patients in whom antibodies against own HLA antigens are detected. SAB testing is associated with technical problems, such as falsepositive results, which mainly originate from reactions of patients sera with denatured antigens and variable antigen densities on the beads. After addition of complement components, such as C1q, complementbinding HLA antibodies can be determined in the single antigen solidphase assay.
80 Criteria for determination of UAM There is general consensus that cytotoxic HLA antibodies should be avoided. Therefore, all HLA class I and class II IgG antibody specificities that were identified in the CDC testing with unseparated lymphocytes or isolated T or B lymphocytes are considered a contraindication to transplantation and must be registered as UAM. In female patients with former pregnancies, either the HLA alleles of their children or the HLA alleles of the children s father should be determined to identify potential immunizing antigen mismatches.
81 Especially under the following conditions, HLA antibody specificities that give positive reactions only in the SAB or in the bead-based multiple antigen test, but are negative in CDC and/or other solid-phase assays, such as bead-pra, flow-pra, ELISA-screen, or ELISA-PRA, should not be considered as UAM : a. if the HLA antibody specificities cannot be supported by the immunization history of the patient. b. if they belong to the unspecific reaction patterns that were previously published to be caused either by natural antibodies or denatured antigens in solid-phase assays.
6/19/2012. Who is in the room today? What is your level of understanding of Donor Antigens and Candidate Unacceptables in KPD?
6/19/212 KPD Webinar Series: Part 3 Demystifying the OPTN Kidney Paired Donation Pilot Program Unacceptable HLA antigens: The key to finding a compatible donor for your patient M. Sue Leffell, Ph.D. J.
More informationMary Keogan, on Mary behalf Keogan of all in NHISSOT On behalf of all in NHISSOT. 4th April 2014
Solid Organ Transplantation How the Lab Contributes to Improved Patient Outcomes Mary Keogan, on Mary behalf Keogan of all in NHISSOT On behalf of all in NHISSOT 4th April 2014 Solid Organ Transplantation
More informationEvaluation of Two New Antibody Detection Techniques in Kidney Transplantation. Doctoral Thesis. Dr. Petra Gombos
Evaluation of Two New Antibody Detection Techniques in Kidney Transplantation Doctoral Thesis Dr. Petra Gombos Semmelweis University Doctoral School of Pathology Supervisor: Dr. Róbert Langer, Ph.D. Consultant:
More informationChapter 10. Histocompatibility Testing
Chapter 10 Histocompatibility Testing Chapter 10 Histocompatibility Testing Table of Contents 10.1 General... 3 10.1.1 Registration of renal transplant patients...3 10.1.2 Material for histocompatibility
More informationSTEP-programme S-candiaT-ransplant kidney E-xchange P-rogramme (STEP) Version 1.8
STEP-programme S-candiaT-ransplant kidney E-xchange P-rogramme (STEP) Version 1.8 June 12, 2017 General guidelines Purpose To increase the likelihood of offering a suitable kidney graft to immunized (HI)
More informationChapter 10. Histocompatibility Testing
Chapter 10 Histocompatibility Testing Change record Date Author Version Change reference 08-03-2013 J. de Boer 2.0 Textual Adjustments 13-09-2012 C.M. Tieken 1.1 Text added page 2 10-03-2012 I. Doxiadis
More informationThe Acceptable Mismatch program of Eurotransplant.
The Acceptable Mismatch program of Eurotransplant. Frans Claas Leiden University Medical Center Eurotransplant Reference Laboratory Leiden, the Netherlands. Hinterzarten, December 7, 2013 Main problem
More informationBasel - 6 September J.-M. Tiercy National Reference Laboratory for Histocompatibility (LNRH) University Hospital Geneva
Basel - 6 eptember 2012 J.-M. Tiercy National Reference Laboratory for Histocompatibility (LNRH) University Hospital Geneva Outline the HLA system is (a) complex anti-hla immunisation and alloreactivity
More informationTransplant Applications of Solid phase Immunoassays Anti HLA antibody testing in solid organ transplantation
AACC Professional Course BETH ISRAEL DEACONESS MEDICAL CENTER HARVARD MEDICAL SCHOOL Transplant Applications of Solid phase Immunoassays Anti HLA antibody testing in solid organ transplantation J. Ryan
More informationMinutes Tissue Typers Meeting Aarhus, 21st September 2018
Minutes Tissue Typers Meeting Aarhus, 21st September 2018 Location: Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus N, relocation to C104 patiently accepted by all participants.
More informationWhy so Sensitive? Desensitizing Protocols for Living Donor Kidney Transplantation
Why so Sensitive? Desensitizing Protocols for Living Donor Kidney Transplantation Stephen J Tomlanovich MD Objectives of this Talk Define the sensitized patient Describe the scope of the problem for a
More informationPilot on inclusion of a case report in the external proficiency testing program
Pilot on inclusion of a case report in the external proficiency testing program Sebastiaan Heidt Eurotransplant Reference Laboratory ET EXTRA MURAL MEETING 2016 Background At the extramural meeting 2015
More informationThe new Banff vision of the role of HLA antibodies in organ transplantation: Improving diagnostic system and design of clinical trials
The new Banff vision of the role of HLA antibodies in organ transplantation: Improving diagnostic system and design of clinical trials Carmen Lefaucheur 1 2 Banff 2015: Integration of HLA-Ab for improving
More informationHistocompatibility Evaluations for HSCT at JHMI. M. Sue Leffell, PhD. Professor of Medicine Laboratory Director
Histocompatibility Evaluations for HSCT at JHMI M. Sue Leffell, PhD Professor of Medicine Laboratory Director JHMI Patient Population Adults Peds NMDP data >20,000 HSCT JHMI HSCT Protocols Bone marrow
More information10/18/2012. A primer in HLA: The who, what, how and why. What?
A primer in HLA: The who, what, how and why What? 1 First recognized in mice during 1930 s and 1940 s. Mouse (murine) experiments with tumors Independent observations were made in humans with leukoagglutinating
More informationHuman Leukocyte Antigens and donor selection
Human Leukocyte Antigens and donor selection Duangtawan Thammanichanond, MD. PhD. Histocompatibility and Immunogenetics Laboratory, Faculty of Medicine Ramathibodi Hospital, Mahidol University Outline
More informationReflections and Future Directions HLA Testing in Transplantation
Reflections and Future Directions HLA Testing in Transplantation Dr. Robert Liwski, MD, PhD, FRCPC Medical Director, HLA Typing Laboratory Division of Hematopathology Professor, Department of Pathology
More informationIs it safe to transplant against HLA DSA in cardiothoracic patients? development and implementation of national Guidelines
Is it safe to transplant against HLA DSA in cardiothoracic patients? development and implementation of national Guidelines Dr Martin Howell. Laboratory Director. Department of H&I, NHS Blood and Transplant,
More informationOrgan transplantation in Bulgaria
Cell Tissue Banking (28) 9:337 342 DOI 1.17/s1561-7-935-2 Organ transplantation in Bulgaria Elissaveta Naumova Æ Petar Panchev Æ Pencho J. Simeonov Æ Anastassia Mihaylova Æ Kalina Penkova Æ Petia Boneva
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,700 108,500 1.7 M Open access books available International authors and editors Downloads Our
More informationThe New Kidney Allocation System (KAS) Frequently Asked Questions
The New Kidney Allocation System (KAS) Frequently Asked Questions Contents General: The Need for the New System and Key Implementation Details... 4 Why was the newly revised KAS necessary?... 4 What were
More informationDesensitization in Kidney Transplant. James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver
Desensitization in Kidney Transplant James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Organ Shortage Currently there are >90,000 patients on the kidney
More informationThe New Kidney Allocation System: What You Need to Know. Anup Patel, MD Clinical Director Renal and Pancreas Transplant Division Barnabas Health
The New Kidney Allocation System: What You Need to Know Anup Patel, MD Clinical Director Renal and Pancreas Transplant Division Barnabas Health ~6% of patients die each year on the deceased donor waiting
More informationStrategies for Desensitization
Strategies for Desensitization Olwyn Johnston MB, MRCPI, MD, MHSc BC Nephrology Day October 8 th 2010 Pre-transplant crossmatch (CMX) with donor lymphocytes has been standard of practice Positive CDC CXM
More information2017 BANFF-SCT Joint Scientific Meeting. BARCELONA March 2017
2017 BANFF-SCT Joint Scientific Meeting BARCELONA 27-31 March 2017 Adriana Zeevi PhD (D) ABHI Professor of Pathology, Surgery and Immunology Director of Histocompatibility Laboratory University of Pittsburgh
More informationOrgan Procurement and Transplantation Network
OPTN Organ Procurement and Transplantation Network POLICIES This document provides the policy language approved by the OPTN/UNOS Board at its meeting in June 2015 as part of the Operations and Safety Committee
More information23/10/2017. Panel Reactive Antibodies and Crossmatch by Flow Cytometry. Antibodies against. Renal transplantation. Antibody mediated rejection (AMR)
Renal transplantation Panel Reactive Antibodies and Crossmatch by Flow Cytometry Katherina Psarra Immunology Histocompatibility Dept Evangelismos Hospital Athens, Greece In spite of the enormous progress
More informationQuantifying HLA-specific antibodies in patients undergoing desensitization Andrea Zachary a and Nancy L. Reinsmoen b
Quantifying HLA-specific antibodies in patients undergoing desensitization Andrea Zachary a and Nancy L. Reinsmoen b a John Hopkins University, Immunogenetics Laboratory, Baltimore, Maryland and b Cedars-Sinai
More informationOPTN/UNOS Policy Notice Review of HLA Tables (2016)
Review of HLA Tables (2016) Sponsoring Committee: Policy/Bylaws Affected: Histocompatibility Policy 4.10 (Reference Tables of HLA Antigen Values and Split Equivalences) Public Comment: July 31, 2017 October
More informationAPHERESIS FOR DESENSITIZATION OF NON-RENAL TRANSPLANTS
APHERESIS FOR DESENSITIZATION OF NON-RENAL TRANSPLANTS GOW AREPALLY, MD MEDICAL DIRECTOR DUKE THERAPEUTIC APHERESIS SERVICE ASSOCIATE PROFESSOR, MEDICINE AMERICAN SOCIETY FOR APHERESIS MAY 25 TH 2013 OVERVIEW
More informationTransplant Nephrology Update: Focus on Outcomes and Increasing Access to Transplantation
Transplant Nephrology Update: Focus on Outcomes and Increasing Access to Transplantation Titte R Srinivas, MD, FAST Medical Director, Kidney and Pancreas Transplant Programs Objectives: Describe trends
More informationCurrent strategies to kidney allocation
Current strategies to kidney allocation Dr Marie Alice Macher Dr Christian Jacquelinet Emilie Savoye Dr Corinne Antoine Direction Prélèvement Greffe organes - tissus From organ sharing to organ allocation
More informationRenal Transplantation: Allocation challenges and changes. Renal Transplantation. The Numbers 1/13/2014
Renal Transplantation: Allocation challenges and changes Mark R. Wakefield, M.D., F.A.C.S. Associate Professor of Surgery/Urology Director Renal Transplantation Renal Transplantation Objectives: Understand
More informationThe MHC and Transplantation Brendan Clark. Transplant Immunology, St James s University Hospital, Leeds, UK
The MHC and Transplantation Brendan Clark Transplant Immunology, St James s University Hospital, Leeds, UK Blood Groups Immunofluorescent staining has revealed blood group substance in the cell membranes
More informationThe Kidney Allocation System Changed in a Substantive Way on December 5, Your Patients Have Been, and Will Be, Affected by These Changes
The Kidney Allocation System Changed in a Substantive Way on December 5, 2014 Your Patients Have Been, and Will Be, Affected by These Changes 1 The New Kidney Allocation System Terms of Importance Pediatric
More informationBackground & objectives
Indian J Med Res 145, February 2017, pp 222-228 DOI: 10.4103/ijmr.IJMR_222_16 Quick Response Code: Comparative analysis of Luminex-based donor-specific antibody mean fluorescence intensity values with
More informationThe Human Major Histocompatibility Complex
The Human Major Histocompatibility Complex 1 Location and Organization of the HLA Complex on Chromosome 6 NEJM 343(10):702-9 2 Inheritance of the HLA Complex Haplotype Inheritance (Family Study) 3 Structure
More informationAntihuman leukocyte antigen (HLA) antibodies can be
Antihuman Leukocyte Antigen Specific Antibody Strength Determined by Complement-Dependent or Solid-Phase Assays Can Predict Positive Donor-Specific Crossmatches Ibrahim Batal, MD; Adriana Zeevi, PhD; John
More informationDE-MYSTIFYING THE BLACK BOX OF TRANSPLANT IMMUNOLOGY
2016 DE-MYSTIFYING THE BLACK BOX OF TRANSPLANT IMMUNOLOGY James H Lan, MD, FRCP(C), D(ABHI) Clinical Assistant Professor, University of British Columbia Nephrology & Kidney Transplantation, Vancouver General
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Clinical Transplantation Laboratory (CTL) 3rd Floor Tower Wing Guy's Hospital SE9 1RT Contact: Jeremy Skinner Tel: +44 (0)2071881713 E-Mail:
More informationEven in this era of efficient immunosuppression, a positive
OVERVIEW Enhanced Kidney Allocation to Highly Sensitized Patients by the Acceptable Mismatch Program Frans H. J. Claas, 1 Axel Rahmel, 2 and IIias I. N. Doxiadis 1 Even in this era of efficient immunosuppression,
More informationExpanding Candidate and Deceased Donor HLA Typing Requirements to Provide Greater Consistency Across Organ Types
At-a-Glance Expanding Candidate and Deceased Donor HLA Typing Requirements to Provide Greater Consistency Across Organ Types Affected/Proposed Policy: 2.8.A (Required Information for Deceased Kidney Donors);
More informationWelche Donor-spezifischen HLA Antikörper sind schädlich?
Welche Donor-spezifischen HLA Antikörper sind schädlich? Prof. Dr. med. Caner Süsal Transplantationsimmunologie Institut für Immunologie Universität Heidelberg Sensitization Alloantibody Production Alloantibodies
More informationDonation and Transplantation Kidney Paired Donation Program Data Report
Donation and Transplantation Kidney Paired Donation Program Data Report 2009-2013 Extracts of the information in this report may be reviewed, reproduced or translated for educational purposes, research
More informationUpdate to the Human Leukocyte Antigens (HLA) Equivalency Tables
Update to the Human Leukocyte s (HLA) Equivalency Tables Sponsoring Committee: Histocompatibility Policy/Bylaws Affected: Policy 2.11.A: Required Information for Deceased Kidney Donors, Policy 2.11.B:
More informationLiving Donor Paired Exchange (LDPE)
Living Donor Paired Exchange (LDPE) Why do we need Living Donation? 3,796 patients waiting for an organ transplant 2,679 (71%) waiting for a kidney transplant 249 people died while waiting for an organ
More informationApplication of Calculated Panel Reactive Antibody Using HLA Frequencies in Koreans
Original Article Diagnostic Immunology Jang J-Y, et al. Ann Lab Med 2012;32:66-72 ISSN 2234-3806 eissn 2234-3814 Application of Calculated Panel Reactive Antibody Using HLA Frequencies in Koreans Ji-Young
More informationHLA Selected Platelets
HLA Selected Platelets Dr PhD Clinical Scientist Department of Histocompatibility & Immunogenetics NHS Blood and Transplant Colindale Poor increment (
More informationIMMUNOBIOLOGY OF TRANSPLANTATION. Wasim Dar
IMMUNOBIOLOGY OF TRANSPLANTATION Wasim Dar Immunobiology of Transplantation Overview Transplantation: A complex immunologic process Contributions Innate Immunity Adaptive immunity T Cells B Cells HLA Consequences
More information25/10/2017. Clinical Relevance of the HLA System in Blood Transfusion. Outline of talk. Major Histocompatibility Complex
Clinical Relevance of the HLA System in Blood Transfusion Dr Colin J Brown PhD FRCPath. October 2017 Outline of talk HLA genes, structure and function HLA and immune complications of transfusion TA-GVHD
More informationCompleting the CIBMTR Confirmation of HLA Typing Form (Form 2005)
Completing the CIBMTR Confirmation of HLA Typing Form (Form 2005) Stephen Spellman Research Manager NMDP Scientific Services Maria Brown Scientific Services Specialist Data Management Conference 2007 1
More informationClinical Study Different Impact of Pretransplant Anti-HLA Antibodies Detected by Luminex in Highly Sensitized Renal Transplanted Patients
BioMed Research International Volume 2013, Article ID 738404, 5 pages http://dx.doi.org/10.1155/2013/738404 Clinical Study Different Impact of Pretransplant Anti-HLA Antibodies Detected by Luminex in Highly
More informationHLA Antibody Complement Based Assays. Howard M. Gebel, PhD, D(ABHI) Robert A. Bray, PhD, D(ABHI) Emory University Hospital Atlanta, GA
HLA Antibody Complement Based Assays Howard M. Gebel, PhD, D(ABHI) Robert A. Bray, PhD, D(ABHI) Emory University Hospital Atlanta, GA Disclosure Neither presenter has any financial relationships related
More informationManagement of platelet refractory patients, why does your patient keep on bleeding? Dr Colin Brown, H&I Dept, NHSBT Colindale
Management of platelet refractory patients, why does your patient keep on bleeding? Dr Colin Brown, H&I Dept, NHSBT Colindale Pooled Platelets (Buffy Coat Derived) Adult dose from 4 ABO-identical donors
More informationAND My presentation does include discussion of off-label or investigational use (empiric therapy)
Managing Sensitized Patients Pre-Heart Transplantation Patricia P. Chang, MD MHS Associate Professor of Medicine Director, UNC Heart Failure & Transplant Program Patricia P. Chang, MD MHS Associate Professor
More informationThe New Kidney Allocation Policy: Implications for Your Patients and Your Practice
The New Kidney Allocation Policy: Implications for Your Patients and Your Practice Clinical Practice Today CME Co-provided by Learning Objectives Upon completion, participants should be able to: Explain
More informationCHAPTER 10 BLOOD GROUPS: ABO AND Rh
CHAPTER 10 BLOOD GROUPS: ABO AND Rh The success of human blood transfusions requires compatibility for the two major blood group antigen systems, namely ABO and Rh. The ABO system is defined by two red
More informationHighly Sensitized Patient Registry: Update and Successes
Highly Sensitized Patient Registry: Update and Successes Dr. Olwyn Johnston Medical Director Kidney and Pancreas Transplant Program Vancouver General Hospital Conflict of Interest Transplant Nephrologist
More informationTransplant Update New Kidney Allocation System Transplant Referral Strategies. Antonia Harford, MD University of New Mexico
Transplant Update New Kidney Allocation System Transplant Referral Strategies Antonia Harford, MD University of New Mexico Financial Disclosures Doctor Harford has received financial support for dialysis
More informationTransfusion support in Transplantation
Transfusion support in Transplantation Patricia Campbell University of Alberta Hospitals University of Alberta Objectives UofA transplant programs What we do and why? HLA and ABO incompatible transplants
More informationNational Transplant Guidelines
National Transplant Guidelines Quo Vadis? Scott Campbell, Princess Alexandra Hospital, Brisbane. Quo Vadis Whither goest thou? Where the F#$% do we go next? Overview WAITING LIST ELIGIBILITY ALLOCATION
More informationShould red cells be matched for transfusions to patients listed for renal transplantation?
Should red cells be matched for transfusions to patients listed for renal transplantation? Dr M.Willicombe Imperial College Renal and Transplant Centre, Hammersmith Hospital Should red cells be matched
More informationOPTN/UNOS Histocompatibility Committee Report to the Board of Directors November 12-13, 2014 St. Louis, MO
OPTN/UNOS Histocompatibility Committee OPTN/UNOS Histocompatibility Committee Report to the Board of Directors November 12-13, 2014 St. Louis, MO Dolly Tyan, Ph.D., Chair Robert Bray, Ph.D., Vice Chair
More informationEvaluation of Two New Antibody Detection Techniques in Kidney Transplantation
Evaluation of Two New Antibody Detection Techniques in Kidney Transplantation Doctoral Dissertation Dr. Petra Gombos Semmelweis University Doctoral School of Pathology Supervisor: Consultant: Official
More informationHISTOCOMPATIBILITY LABORATORIES
HISTOCOMPATIBILITY LABORATORIES SERVICE PROVISION USER GUIDE DOC45 Version 004 September 2015 Page 1 of 23 CONTENTS CONTENTS... 1 SERVICE PROVISION INTRODUCTION... 3 SUMMARY... 4 PROCEDURES UNDERTAKEN
More informationDesensitization for solid organ and hematopoietic stem cell transplantation
Andrea A. Zachary Mary S. Leffell Desensitization for solid organ and hematopoietic stem cell transplantation Authors address Andrea A. 1 Zachary, Mary S. Leffell 1 1 Department of Medicine, Division of
More informationDonor-Specific HLA Class I and CREG Antibodies in Complement-Dependent Cytotoxicity-Negative Renal Transplants
Available online at www.annclinlabsci.org 330 Annals of Clinical & Laboratory Science, vol. 40, no. 4, 2010 Donor-Specific HLA Class I and CREG Antibodies in Complement-Dependent Cytotoxicity-Negative
More informationFAIRNESS/EQUITY UTILITY/EFFICACY EFFICIENCY. The new kidney allocation system (KAS) what has it done? 9/26/2018. Disclosures
The new kidney allocation system (KAS) what has it done? Disclosures No financial disclosure Ryutaro Hirose, MD Professor in Clinical Surgery University of California San Francisco Objectives Describe
More informationDEFINITIONS OF HISTOCOMPATIBILITY TYPING TERMS
DEFINITIONS OF HISTOCOMPATIBILITY TYPING TERMS The definitions below are intended as general concepts. There will be exceptions to these general definitions. These definitions do not imply any specific
More informationPredicting HLA Class II Alloantigen Immunogenicity From the Number and Physiochemical Properties of Amino Acid Polymorphisms
CLINICAL AND TRANSLATIONAL RESEARCH Predicting HLA Class II Alloantigen Immunogenicity From the Number and Physiochemical Properties of Amino Acid Polymorphisms Vasilis Kosmoliaptsis, 1,2,6 Linda D. Sharples,
More informationEffects of HLA-Matched Blood Transfusion for Patients Awaiting Renal Transplantation
CLINICAL AND TRANSLATIONAL RESEARCH Effects of HLA-Matched Blood Transfusion for Patients Awaiting Renal Transplantation Bernadette A. Magee, 1,4 Jeanie Martin, 1 Miceal P. Cole, 1 Kieran G. Morris, 2
More informationPaired Donation. Andrew Bradley Rachel Johnson Joanne Allen Susan V Fuggle. Cambridge University NHS Hospitals NHS Foundation trust
Paired Donation Andrew Bradley Rachel Johnson Joanne Allen Susan V Fuggle Cambridge University NHS Hospitals NHS Foundation trust Showing a preference 1860 John Calcott Horsley UK Living Donor kidney transplant
More informationThree Sides to Allocation. ECD Extended Criteria Donor
Kidney Allocation- Optimal Use of Deceased Donors The New US System..and impact on wait list management Three Sides to Allocation Justice Peter G Stock MD, PhD Utility Efficiency Standard Criteria Donor
More informationDonation & Transplantation Interprovincial Programs Report
Donation & Transplantation Interprovincial Programs Report 29-214 Donation & Transplantation Interprovincial Programs Report 9-214 TERMINOLOGY & USE OF DATA A glossary of terms can be found in Appendix
More informationMempersiapkan transplantasi ginjal (resipien dan donor) Dr. Atma Gunawan SpPD.KGH
Mempersiapkan transplantasi ginjal (resipien dan donor) Dr. Atma Gunawan SpPD.KGH Who is recipient? All patient ESRD Absolute KI : - Transplant candidate with cirrhosis - Active malignancy - Severe respiratory
More informationIMPACT OF PREFORMED AND DE NOVO ANTI-HLA DP ANTIBODIES
IMPACT OF PREFORMED AND DE NOVO ANTI-HLA DP ANTIBODIES IN RENAL ALLOGRAFT SURVIVAL Dolores Redondo-Pachón 1, Julio Pascual 1*, María J. Pérez-Sáez 1, Carmen García 2, Juan José Hernández 2, Javier Gimeno
More informationTreatment of Chronic Antibody Mediated Rejection
Treatment of Chronic Antibody Mediated Rejection Robert A. Montgomery MD, DPhil Professor of Surgery Director of the NYU Langone Transplant Institute Disclosures: Served on Advisory Boards for Genentech
More informationClinical Relevance of the HLA System in Blood Transfusion. Dr Colin J Brown PhD FRCPath. October 2017
Clinical Relevance of the HLA System in Blood Transfusion Dr Colin J Brown PhD FRCPath. October 2017 Outline of talk HLA genes, structure and function HLA and immune complications of transfusion TA-GVHD
More informationHong Kong Journal Nephrol of 2000;(2): Nephrology 2000;2(2): BR HAWKINS ORIGINAL A R T I C L E A point score system for allocating cadaver
Hong Kong Journal Nephrol of 2000;(2):79-83. Nephrology 2000;2(2):79-83. ORIGINAL A R T I C L E A point score system for allocating cadaveric kidneys for transplantation based on patient age, waiting time
More informationArchive of Organ Transplantation
v Clinical Group Archive of Organ Transplantation DOI CC By Shafiq Ahmad Chughtai 1, Ajay Kumar Sharma 2 * and Ahmed Halawa 3 1 Registrar Renal Transplantation, Leicester, UK 2 Royal Liverpool University
More informationSerum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant
SDC, Patients and Methods Complement-dependent lymphocytotoxic crossmatch test () Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant donor-specific CXM was
More informationKIDNEY ALLOCATION SYSTEM (KAS) OUT-OF-THE-GATE MONITORING. Report #3: January 13, 2015
KIDNEY ALLOCATION SYSTEM (KAS) OUT-OF-THE-GATE MONITORING Report #3: January 13, 2015 Purpose: Provide an early look at high-level metrics revealing performance of the system, and detect unanticipated
More informationThe role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness.
The role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness. Robert Liwski, MD, PhD, FRCPC Medical Director HLA Typing Laboratory Department of Pathology Dalhousie
More informationKidney paired donation in the presence of donor-specific antibodies
http://www.kidney-international.org & 2013 International Society of Nephrology clinical investigation Kidney paired donation in the presence of donor-specific antibodies Jeremy M. Blumberg 1, Hans A. Gritsch
More informationHuman leukocyte antigen (HLA) matching has a beneficial
IMMUNOBIOLOGY AND GENOMICS Predicting the Immunogenicity of Human Leukocyte Antigen Class I Alloantigens Using Structural Epitope Analysis Determined by HLAMatchmaker Vasilis Kosmoliaptsis, 1,2 J. Andrew
More informationEculizumab chez les receveurs de greffe rénal à haut risque immunologique. Mark D. Stegall Mayo Clinic, Rochester, MN
Eculizumab chez les receveurs de greffe rénal à haut risque immunologique Mark D. Stegall Mayo Clinic, Rochester, MN Disclosure. Dr Mark Stegall. Institution : Mayo Clinic, Rochester. Research contracts
More informationA Guide to Better Living
Transplantation What Is a Kidney Transplant? Kidney transplantation is placing a kidney from one person (donor) into a patient with kidney failure (recipient). This is done by surgery where the donated
More informationBlood Component Testing and Labeling
Blood Component Testing and Labeling Each donor unite must be tested and properly labeled before its release for transfusion. Required Tests: In most blood banks, pretransfusion testing involves determining
More informationReview Article Clinical Relevance of HLA Antibody Monitoring after Kidney Transplantation
Hindawi Publishing Corporation Journal of Immunology Research Volume 2014, Article ID 845040, 5 pages http://dx.doi.org/10.1155/2014/845040 Review Article Clinical Relevance of HLA Antibody Monitoring
More informationUpdate on Kidney Allocation
Update on Kidney Allocation 23rd Annual Conference Association for Multicultural Affairs in Transplantation Silas P. Norman, M.D., M.P.H. Associate Professor Division of Nephrology September 23, 2015 Disclosures
More information3/6/2017. Prevention of Complement Activation and Antibody Development: Results from the Duet Trial
Prevention of Complement Activation and Antibody Development: Results from the Duet Trial Jignesh Patel MD PhD FACC FRCP Medical Director, Heart Transplant Cedars-Sinai Heart Institute Disclosures Name:
More informationDr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION
Benjamini. Ch. 19, Pgs 379-399 Page 1 of 10 TRANSPLANTATION I. KINDS OF GRAFTS II. RELATIONSHIPS BETWEEN DONOR AND RECIPIENT Benjamini. Ch. 19, Pgs 379-399 Page 2 of 10 II.GRAFT REJECTION IS IMMUNOLOGIC
More informationSignificance of the MHC
CHAPTER 7 Major Histocompatibility Complex (MHC) What is is MHC? HLA H-2 Minor histocompatibility antigens Peter Gorer & George Sneell (1940) Significance of the MHC role in immune response role in organ
More informationUNIVERSITY OF CALGARY. Characteristics of Donor-Specific anti-hla Antibodies (DSA) Impacting different Renal. Allograft Outcomes. Salim S.
UNIVERSITY OF CALGARY Characteristics of Donor-Specific anti-hla Antibodies (DSA) Impacting different Renal Allograft Outcomes by Salim S. Ghandorah A THESIS SUBMITTED TO THE FACULTY OF GRADUATE STUDIES
More informationHISTOCOMPATIBILITY LABORATORIES
HISTOCOMPATIBILITY LABORATORIES SERVICE PROVISION USER GUIDE Page 1 of 22 CONTENTS SERVICE PROVISION INTRODUCTION... 3 SUMMARY... 4 PROCEDURES UNDERTAKEN FOR HAEMATOPOIETIC STEM CELL TRANSPLATATION...
More informationHLA and Non-HLA Antibodies in Transplantation and their Management
HLA and Non-HLA Antibodies in Transplantation and their Management Luca Dello Strologo October 29 th, 2016 Hystory I 1960 donor specific antibodies (DSA): first suggestion for a possible role in deteriorating
More informationRole of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT
Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT Stephen Spellman, MBS Director, Immunobiology and Observational Research Assistant Scientific Director CIBMTR,
More informationUnderstanding crossmatch testing in organ transplantation: A case-based guide for the general nephrologistnep_
Nephrology 16 (2011) 125 133 Review Article Understanding crossmatch testing in organ transplantation: A case-based guide for the general nephrologistnep_1414 125..133 WILLIAM R MULLEY 1,2 and JOHN KANELLIS
More informationCHAPTER 3 LABORATORY PROCEDURES
CHAPTER 3 LABORATORY PROCEDURES CHAPTER 3 LABORATORY PROCEDURES 3.1 HLA TYPING Molecular HLA typing will be performed for all donor cord blood units and patients in the three reference laboratories identified
More informationDonor-derived Cell-free DNA Improves DSA-informed Diagnosis of ABMR in Kidney Transplant Patients
Donor-derived Cell-free DNA Improves DSA-informed Diagnosis of ABMR in Kidney Transplant Patients Stanley C. Jordan, MD Director, Division of Nephrology Medical Director, Kidney Transplant Program Medical
More information